Abraham Research PLLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$696	1
2024	Research	$8,144	2
2023	Research	$12,215	2
2022	Research	$4,362	3
2021	Research	$75,538	20
2020	Research	$40,197	6
2019	Research	$106,745	10

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $159,058 24 payments
AstraZeneca AB $41,113 4 payments
Shionogi Inc $38,240 9 payments
Sanofi US Services Inc. $9,276 6 payments
GlaxoSmithKline, LLC. $208 1 payment

Studies the money was for Research payments · program years 2019–2025

PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long-acting B2 Agonist and Chronic Oral Corticosteroid Therapy $53,991 8 payments
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $41,113 4 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $41,026 2 payments
Evaluation of S-600918 in Adults With Refractory Chronic Cough $38,240 9 payments
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $21,415 4 payments
A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $21,321 4 payments
A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 $21,054 5 payments
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial $9,276 6 payments
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe Uncontrolled Asthma Patients With Eosinophilic Inflammation $251 1 payment
A Multinational, Single Arm, Observational Study to Evaluate the Real- $208 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.